secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001628280-23-037353
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows
--------------------------------------------------------------------------------

- Product revenue $69.2M, up 22% YoY; VYVGART contributed $4.9M since September launch.
- Net loss $69.2M vs $161.2M in Q3 2022; R&D expenses fell to $58.8M from $99.5M.
- Cash $822.2M at Sept 30, down from $876.4M at June 30, 2023.
- Terminated ZL-1211 (Claudin18.2) development; appointed Dr. Robert Brown as CMO, Oncology.
- Expects at least seven product launches in 2-3 years; multiple NDAs under review (repotrectinib, odronextamab).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/0001628280-23-037353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/zlab-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer